Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 16;12(12):e007571. doi: 10.1161/CIRCEP.119.007571

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Circulation: Arrhythmia and Electrophysiology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — A unified genotype-independent therapy for long QT syndrome (LQTS) type 1 (LQT1), LQTS type 2 (LQT2), and LQTS type 3 (LQT3). A, Steady-state activation (d_∞) and inactivation (f_∞) curves for I_Ca,L. Dashed curve is f_∞ with a 5-mV shift. B, Action potential and I_Ca,L before and after 5-mV shift of f_∞. Left, Normal action potential in which the shift causes no change (the green and blue curves are superimposed). Right, The early afterdepolarization was suppressed by the 5-mV shift but with no change in peak I_Ca,L. C, ECG before (reproduced from Figures 2, 4, and 5) and after a 5-mV f_∞ shift in LQT1, LQT2, and LQT3. D, P_Ca threshold for premature ventricular complexes (PVCs) in 1-dimensional cable simulations vs voltage shift of f_∞ for LQT1, LQT2, and LQT3.